Immix Biopharma Inc. (NASDAQ: IMMX)
$2.05
-0.0050 ( -0.24% ) 19.9K
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Market Data
Open
$2.05
Previous close
$2.05
Volume
19.9K
Market cap
$52.41M
Day range
$1.98 - $2.09
52 week range
$1.55 - $7.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | May 20, 2024 |
4 | Insider transactions | 1 | May 14, 2024 |
4 | Insider transactions | 1 | May 14, 2024 |
10-q | Quarterly Reports | 63 | May 09, 2024 |
ars | Annual reports | 1 | Apr 30, 2024 |
def | Proxies and info statements | 1 | Apr 29, 2024 |
10-k | Annual reports | 78 | Mar 29, 2024 |
8-k | 8K-related | 19 | Feb 06, 2024 |
8-k | 8K-related | 14 | Feb 05, 2024 |
4 | Insider transactions | 1 | Dec 12, 2023 |